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tion was analyzed on national level, data was given by
the National Statistical Office, which includes the in-patient
and outpatient drug use in the number of boxes, from
which DDD (defined daily dose) was calculated. Drug
use between 1994–1999 was measured in specialised hos-
pitals, data was given by the central pharmacy also in the
number of boxes, from which DDD was calculated as
well. We asked 321 patents about their pharmacy bills
for one month concerning anti-asthma drugs. RESULTS:
The incidence and prevalence of bronchial asthma is in-
creasing by 10 thousand patients each year, in the last 10
years the number of asthmatics was doubled. Drug con-
sumption has not changed dramatically between 1989–
1998, on national level a continuous slow increase can be
seen in the ATC groups RO3A, RO3B, RO3C, RO6A. It
is interesting that the use of drugs that belong to group
RO3D (xantines) was increasing until 1997, then it
stopped and a decrease started. The same tendency can
be seen at the hospitals in the xantines and in the inhaled
2 agonist and other inhaled agents except steroids.
Drugs, which are in the other ATC groups, do not show
big changes in the examined period. The use of the in-
haled steroids show smaller changes, a decrease can be
seen in this group as well in the year 1997. The amount
of the used anti-asthma drugs in hospitals compared to
the total drug use for in-patients was 0,3% in average. In
1999 the co-payment (patients with asthma have to pay
only 10% of the actual drug price, 90% is paid by the
National Health Insurance Fund) was the following for
the different severity groups: in mild intermittent (step1)
cases 652,58  643 Forints, in mild persistent (step2)
cases 1355,9  753 Forints, in moderate (step3) cases
2013,21  803 Forints, in severe cases 2310,05  685
Forints. 250 Forints  1 $. CONCLUSION: we can say
that asthma costs are substantial even though the
monthly drug costs might seem low both to the patient
and to the Hungarian National Health Insurance Com-
pany. Chronic asthma is mainly treated in outpatient de-
partments, this fact can be proved by the relatively low
anti-asthma drug consumption in hospital for the inpa-
tient. Our results show no correlation in general between
the number of asthma patients and the rate of drug con-
sumption.
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OBJECTIVES: To investigate resource utilization during
treatment of asthma exacerbation within Primary Care
centres throughout Spain. METHODS: Investigators re-
cruited patients at 10 centres using wide inclusion criteria
and international guidelines (GINA) to define asthma ex-
acerbations and resolution using usual clinical practice.
Information on utilization of healthcare services, re-
sources and asthma medication was recorded prospec-
tively on a standard case report form during each pa-
tient’s exacerbation. RESULTS (preliminary): Of 133
patients recruited, 74% were female. The mean age was
48 (SD 20) years; nearly one third (32%) were aged 45–
65, with a similar proportion (30%) aged 25–45. One
third (33%; 44/133) of patients were in paid employ-
ment; almost twice as many of these were female (22%)
than male (11%). On average, each patient made 2.9 (SD
1.4) visits to the Primary Care centre; 95% of these con-
sultations were with a doctor. Medication was prescribed
and tests were performed for 76% (101) of patients.
Only one patient (with a mild exacerbation) was referred
to hospital as an outpatient; there were no emergency ad-
missions. Asthma exacerbation medication summarised
by drug group and exacerbation severity is as follows.
CONCLUSIONS: This study gave a clear picture of
Spanish treatment and prescribing patterns during asthma
exacerbations, and can be useful as a baseline assessment
against which changes in management can be assessed.
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INTRODUCTION: Morbidity and mortality associated
to the respiratory syncytial virus (RSV) disease induce
costs presumed important. The assessment of the macro-
economic impact of the infection is for one part based on
the knowledge of the epidemiological data and further on
the evaluation of the cost of the infected patient. Follow-
ing the WHO, the world annual incidence would be 60
to 65 million cases. The proportion represented by the
elderly is little documented. Nevertheless, because of an
upcoming interest in the health sector for diagnostic and
prophylactic treatment, new data appear and make ap-
pear the RSV as an emerging pathology. The incidence of
RSV infections with the elderly could be 5 to 10% in the
winter. In the non-institutionalized patient, the hospital-
ization probability for complication is estimated, accord-
ing to publications, to 1 to 5%. However, for the subject
Drug group
Mild
(N  58)
Moderate
(N  58)
Severe
(N  17)
Oral steroids 15 (26%) 20 (34%) 14 (82%)
Inhaled steroids 31 (53%) 44 (76%) 13 (76%)
Bronchodilator 14 (24%) 15 (26%) 7 (41%)
Short acting beta-agonists 33 (57%) 30 (52%) 8 (47%)
Long acting beta-agonists 11 (19%) 17 (29%) 6 (35%)
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with a risk factor, (heart and respiratory failure) the res-
piratory infection probability is 4.3%, inducing hospital-
izations in 37% of cases. RESULTS: Direct costs were
calculated as the sum of costs due to medication, consul-
tations, hospitalization and respiratory physiotherapy.
The impact of indirect cost should also be taken into con-
sideration. Our estimation evaluated them four times in-
ferior to those due to influenza. With regards to the risk
of hospitalization (1%–3% or 5%), the average cost of
RSV infection varies, according to a societal perspective,
from 750 to 1103 Euros. CONCLUSION: The annual fi-
nancial burden of RSV disease from the payer perspective
would be between 306 to 612 millions Euros. This an-
nual figure represents a third of the cost allocated to in-
fluenza, which justifies the efforts of research in view of
making emerge a vaccine against the RSV.
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OBJECTIVES: Asthma bronchiale (AB) and chronic bron-
chitis (CB) are common chronic disorders with high rates
of prevalence. We performed a cost of illness study that
aimed to assess the economic burden of these disorders in
Germany. To the best of our knowledge, we used the first
time data for entire Germany, in contrast with the few
previous studies. METHODS: We obtained in a retro-
spective analysis secondary data from governmental insti-
tutions as well as from pharmaceutical industry. Re-
source use was based on 1996 schedules and costs were
estimated in 1996 DM. We chose the cost perspective of
sickness funds to estimate direct costs. The human capital
approach was applied for the calculation of indirect
costs. RESULTS: Total estimated costs were DM 5.81
billion related to AB, and DM 20.17 billion related to
CB. We did not include outpatient physician services in
the calculation of direct costs in lack of adequate data.
Therefore, direct costs represented only 33% and 22% of
total estimated costs, respectively. The most important
cost driver of direct costs was outpatient prescribed med-
icines, followed by hospitalization. Outpatient prescribed
medicines accounted for 55% and 63% of the direct
costs, respectively. Of the indirect costs of AB 43% were
associated with early retirement. Loss of work was with
75% by far the largest single cost driver of indirect costs
due to CB. CONCLUSIONS: Findings from this study
for Germany show the evident importance of outpatient
prescribed medicines as cost driver of direct costs of AB
as well as of CB. Furthermore, this study underlines the
major role of loss of work concerning indirect costs of
CB. The data suggest that therapeutic progress and cessa-
tion of smoking can provide distinctive savings of direct
costs and even more of indirect costs of AB and CB.
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OBJECTIVE: To determine the appropriateness of using
prescription treatment to measure asthma severity in a
retrospective claims database. METHODS: All patients
within PharMetric’s Integrated Outcomes Database pos-
sessing a diagnosis of asthma (ICD-9-CM  493) and a
prescription claim for an asthma medication during 1997–
1998, were eligible for study inclusion. Patients with less
than 12 months of enrollment following the initial asthma
diagnosis, or a diagnosis of chronic obstructive pulmo-
nary disease (COPD) or cystic fibrosis (CF) were ex-
cluded from the analysis. Patients were assigned into se-
verity levels based on the combination of asthmatic
regimens received during the study period: Level 1 
Short Acting Beta Agonist (SABA) Only; Level 2  one
controller medication (Mast Cell Stabilizer, Inhaled Corti-
costeroid, or Leukotriene Modifying Agent); Level 3  2
Controllers (above list  Long Acting Beta Agonis); Level
4  3 or more controllers (above list  Long Acting Beta
Agonist). Patient demographics, asthma-specific charges,
and comorbid conditions were captured for each patient
during the study period. RESULTS: 124,076 patients met
the inclusion criteria. The mean age was 23.6 years (SD 
19.6), and 53.0% were female. Over half (50.5%) of pa-
tients were in Level 1, while only 0.9% were in Level 4.
Mean age and percentage of females increased with in-
creasing severity. The mean annual asthma-specific charge
per patient was $675.73 (SD  $1992.10), and ranged
from $379 for Level 1 patients to $1,414 for Level 4 pa-
tients. Prevalence of diabetes, hypertension, and depres-
sion increased with increasing severity, while upper-
respiratory and lower-respiratory infections decreased.
CONCLUSION: The use of treatment regimen appears
to be a viable alternative for measuring severity of asthma
in retrospective analyses, however further research is needed.
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BACKGROUNDS: Nonsteroidal anti-inflammatory drugs
(NSAIDs) are used in nearly every patient with rheuma-
toid arthritis (RA) but their use can be associated with
